AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 5 - (NewsRx.com & NewsRx.net) -- Immune system cells genetically redesigned to recognize immunogen show promise for treating cancer, United States government researchers indicate.
According to a new study, "an effective immune response against cancer requires the activation and expansion of specific T cells. Tumor antigens, however, are generally poor immunogens. To achieve expansion of tumor-reactive T cells in vivo, we used a strategy of generating dual-specific T cells that could respond to a powerful immunogen while also possessing tumor reactivity."
"We generated dual-specific T cells by genetic modification of alloreactive T cells with a chimeric receptor recognizing folate-binding protein, an ovarian cancer-associated antigen. Mouse dual-specific T cells responded in vitro to both allogeneic antigen and tumor cells expressing folate-binding protein, and expanded in number in vivo in response to immunization with allogeneic cells," said M.H. Kershaw and coauthors, NCI, Center for Cancer Research.
"Most ...
Source: HighBeam Research, Dual-specific T cells knock out tumors with double punch.